CD8A and breast carcinoma: In particular, RGS16 has been suggested as a new therapeutic target for breast cancer.[5] Recent studies mainly focus on chronic metabolic acidosis (MET),[57] ovarian cancer,[58] promotes antitumor CD8 T cell exhaustion,[59] bioactive lipid accumulation, and hepatic inflammation.[60] The primary bone cell and primary hepatocyte were mainly used.